Breast cancer is one of the leading causes of cancer related deaths and morbidity among women worldwide. Identifying new targets and developing new therapies is very important in order to improve patient outcomes and minimize this health burden. MicroRNAs, a type of non-coding RNA, are potential targets since they can regulate protein expression in a variety of biological and pathological processes, including cancer. We were interested in identifying drugs that could target microRNAs and reverse or arrest the cancer phenotype. To this end, we performed a screening for small molecule inhibitors that can target two oncogenic microRNAs: miR-10b and miR-21. Two cell based models (MDA-MB-231 and MCF07) were chosen to test the ability of these compounds to inhibit these microRNAs. Cells were treated with different concentrations of the compounds at time points. Real-time PCR was performed to determine if the oncogenic microRNAs were effectively inhibited. The results of the screen seem to be dependent on cellular model. Further experiments are required to elucidate the effectiveness of these drugs and organic compounds as well as their mechanism of action.
This presentation is supported by the National Cancer Institute through the U54 CA096297/CA096300: UPR/MDACC Partnership for Excellence in Cancer Research Training Program.
Cite this work
Researchers should cite this work as follows: